Zealand Pharma A/S

LSE:0NZU Stock Report

Market Cap: DKK 29.5b

Zealand Pharma Valuation

Is 0NZU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0NZU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
DKK 179.28
Fair Value
133.1% overvalued intrinsic discount
12
Number of Analysts

Below Fair Value: 0NZU (DKK417.93) is trading above our estimate of fair value (DKK179.28)

Significantly Below Fair Value: 0NZU is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0NZU?

Key metric: As 0NZU barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0NZU. This is calculated by dividing 0NZU's market cap by their current book value.
What is 0NZU's PB Ratio?
PB Ratio3.5x
BookDKK 8.31b
Market CapDKK 29.49b

Price to Book Ratio vs Peers

How does 0NZU's PB Ratio compare to its peers?

The above table shows the PB ratio for 0NZU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.5x
GNS Genus
2.7x46.67%UK£1.4b
OXB Oxford Biomedica
5.6x82.05%UK£320.1m
BVXP Bioventix
12.7xn/aUK£143.7m
PRTC PureTech Health
1x-90.44%UK£314.2m
0NZU Zealand Pharma
3.5x-18.33%DKK 29.5b

Price-To-Book vs Peers: 0NZU is good value based on its Price-To-Book Ratio (3.5x) compared to the peer average (5.5x).

Price to Book Ratio vs Industry

How does 0NZU's PB Ratio compare vs other companies in the GB Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
LLAI LungLife AI
0.2x100.97%US$1.38m
0HMP Bellerophon Therapeutics
0.1xn/aUS$489.31k
No more companies available in this PB range
0NZU 3.5xIndustry Avg. 2.5xNo. of Companies5PB01.22.43.64.86+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0NZU is expensive based on its Price-To-Book Ratio (3.5x) compared to the UK Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is 0NZU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0NZU PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0NZU's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0NZU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 417.93
DKK 934.42
+123.58%
14.22%DKK 1,120.00DKK 750.00n/a12
May ’26DKK 474.04
DKK 936.38
+97.53%
14.94%DKK 1,120.00DKK 730.00n/a13
Apr ’26DKK 476.88
DKK 955.92
+100.45%
15.59%DKK 1,150.00DKK 730.00n/a13
Mar ’26DKK 668.34
DKK 947.85
+41.82%
12.69%DKK 1,100.00DKK 730.00n/a13
Feb ’26DKK 737.46
DKK 1,007.64
+36.64%
9.36%DKK 1,100.00DKK 750.00n/a11
Jan ’26DKK 719.55
DKK 1,012.18
+40.67%
9.63%DKK 1,100.00DKK 750.00n/a11
Dec ’25DKK 733.17
DKK 1,015.00
+38.44%
10.37%DKK 1,100.00DKK 815.00n/a11
Nov ’25DKK 825.26
DKK 1,007.89
+22.13%
11.69%DKK 1,106.00DKK 800.00n/a9
Oct ’25DKK 820.00
DKK 1,022.29
+24.67%
10.31%DKK 1,106.00DKK 800.00n/a7
Sep ’25DKK 889.50
DKK 1,015.14
+14.13%
10.00%DKK 1,106.00DKK 800.00n/a7
Aug ’25DKK 931.00
DKK 989.86
+6.32%
9.59%DKK 1,100.00DKK 800.00n/a7
Jul ’25DKK 924.99
DKK 918.00
-0.76%
12.22%DKK 1,100.00DKK 800.00n/a6
Jun ’25DKK 626.23
DKK 785.57
+25.45%
8.94%DKK 840.00DKK 625.00n/a7
May ’25DKK 627.00
DKK 782.00
+24.72%
10.03%DKK 840.00DKK 600.00DKK 474.047
Apr ’25DKK 681.50
DKK 754.29
+10.68%
14.38%DKK 840.00DKK 570.00DKK 476.887
Mar ’25DKK 653.62
DKK 598.67
-8.41%
26.15%DKK 800.00DKK 382.00DKK 668.346
Feb ’25DKK 470.36
DKK 423.33
-10.00%
11.18%DKK 485.00DKK 355.00DKK 737.466
Jan ’25DKK 377.98
DKK 379.00
+0.27%
11.69%DKK 430.00DKK 295.00DKK 719.556
Dec ’24DKK 331.50
DKK 365.33
+10.21%
9.32%DKK 400.00DKK 295.00DKK 733.176
Nov ’24DKK 299.00
DKK 343.83
+14.99%
9.28%DKK 380.00DKK 295.00DKK 825.266
Oct ’24DKK 317.00
DKK 343.83
+8.46%
9.28%DKK 380.00DKK 295.00DKK 820.006
Sep ’24DKK 256.50
DKK 314.50
+22.61%
12.48%DKK 380.00DKK 270.00DKK 889.506
Aug ’24DKK 237.20
DKK 295.17
+24.44%
11.35%DKK 340.00DKK 235.00DKK 931.006
Jul ’24DKK 240.37
DKK 295.17
+22.80%
11.35%DKK 340.00DKK 235.00DKK 924.996
Jun ’24DKK 264.60
DKK 295.17
+11.55%
11.35%DKK 340.00DKK 235.00DKK 626.236
May ’24DKK 224.48
DKK 291.83
+30.01%
11.26%DKK 340.00DKK 235.00DKK 627.006
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
DKK 936.27
Fair Value
55.4% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 01:58
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zealand Pharma A/S is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura HindleyBerenberg
Kerry HolfordBerenberg
Charlie HaywoodBofA Global Research